molecules-logo

Journal Browser

Journal Browser

The Anticancer Drugs

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2261

Special Issue Editors

Department of Tissue Engineering, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, 87-100 Torun, Poland
Interests: anticancer therapy; personalized oncology; new drug development; microbiome; immunotherapy; cancer microenvironment; cancer cells culture; cancer stem cells
Special Issues, Collections and Topics in MDPI journals
Department of Oncology, Collegium Medicum, Nicolaus Copernicus University, Lukasiewicza str. 1, 85-821 Bydgoszcz, Poland
Interests: molecular markers of the effectiveness of oncological treatment; epigenetic factors affecting clinical decisions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a serious problem that presents a huge threat to human health. During the last few years, there has been continued progress in anticancer drug development.

New agents ranging from small molecules to engineered antibodies and immune modulators have been approved for cancer treatment. Targeting drugs specifically to cancer cells can minimize the toxic effects on normal, healthy cells.

This Special Issue on “The Anticancer Drugs” aims to be an open forum where researchers may share their experiences and findings in this promising field. It is focused on the comprehensive and critical examination of current and emerging research on the design and development of advanced anticancer and their application to experimental and clinical therapeutics.

Contributions to this issue, in the form of both original research and review articles, may cover all aspects of new discovery and development of new therapeutic agents for cancer, using the newest techniques of biotechnology, pharmacology, and genetic engineering.

Prof. Dr. Anna Bajek
Prof. Dr. Krzysztof Roszkowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer therapy
  • drug development
  • personalized cancer treatment
  • nanotechnology
  • drug resistance in cancer
  • drug design
  • resistance
  • targeted therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 808 KiB  
Review
Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights
by Qian Zhou, Yichen Xu, Yan Zhou and Jincheng Wang
Molecules 2022, 27(9), 2685; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27092685 - 21 Apr 2022
Cited by 3 | Viewed by 1887
Abstract
Brain tumors are the most widespread malignancies in children around the world. Chemotherapy plays a critical role in the treatment of these tumors. Although the current chemotherapy process has a remarkable outcome for a certain subtype of brain tumor, improving patient survival is [...] Read more.
Brain tumors are the most widespread malignancies in children around the world. Chemotherapy plays a critical role in the treatment of these tumors. Although the current chemotherapy process has a remarkable outcome for a certain subtype of brain tumor, improving patient survival is still a major challenge. Further intensive treatment with conventional non-specific chemotherapy could cause additional adverse reactions without significant advancement in survival. Recently, patient derived brain tumor, xenograft, and whole genome analysis using deep sequencing technology has made a significant contribution to our understanding of cancer treatment. This realization has changed the focus to new agents, targeting the molecular pathways that are critical to tumor survival or proliferation. Thus, many novel drugs targeting epigenetic regulators or tyrosine kinase have been developed. These selective drugs may have less toxicity in normal cells and are expected to be more effective than non-specific chemotherapeutics. This review will summarize the latest novel targets and corresponding candidate drugs, which are promising chemotherapy for brain tumors according to the biological insights. Full article
(This article belongs to the Special Issue The Anticancer Drugs)
Show Figures

Figure 1

Back to TopTop